We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Accelerate Diagnostics Announces Launch of Accelerate Arc™ Module and BC Kit

Accelerate Diagnostics Announces Launch of Accelerate Arc™ Module and BC Kit content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, has announced the launch of the Accelerate Arc system, comprised of the Arc Module and BC Kit, an automated path to rapid and accurate microbial identification for positive blood cultures.

Designed for labs with MALDI, the Accelerate Arc Module is a novel application of inline centrifugal and sample preparation techniques, providing a suspension of cleaned and concentrated microbial cells, which together with the blood culture (BC) kit, allow for direct transfer to a MALDI spotting plate.

The simple load-and-go workflow eliminates the need for batching multiple specimen tests, cutting hours off the wait for microbial ID results for positive blood cultures. The Arc module requires just 2-3 minutes of hands-on time to run  and is simple enough to be used on all shifts, by any laboratory technician.

In addition, the Accelerate Arc system is designed to eliminate the need for overnight culture incubation for current MALDI users, while reducing the likelihood of cross reactivity and potential false positive results that come with rapid multi-targeted molecular tests. For some labs, roughly 30% of molecular tests turn up as contaminants, increasing the number of expensive rapid multi-targeted molecular kits that are wasted.

“I am excited to be launching this new system as promised and with strong early performance data.  The total cost to rapidly identify organisms from positive blood cultures could be at least fifty percent less than what you’re paying today for a rapid molecular ID solution,” said Jack Phillips, President, and CEO of Accelerate Diagnostics. “When you think of the extreme pressure that labs are under today, the Arc is a fast and inexpensive diagnostic tool which frees up valuable technician time by automating the MALDI workflow.

Recent studies conducted on the efficacy and time-saving benefits of the Arc study will be presented at the upcoming 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022). The Arc is currently intended for Research Use Only and is not for use in diagnostic procedures.